Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Abstract Blood pressure measurements form a critical component of adverse event monitoring for tyrosine kinase inhibitors, but might also serve as a biomarker for dose titrations. This study explored the impact of various sources of within‐individual variation on blood pressure readings to improve m...

Podrobná bibliografie
Hlavní autoři:	Maddalena Centanni, Abel Thijs, Ingrid Desar, Mats O. Karlsson, Lena E. Friberg
Médium:	Článek
Jazyk:	English
Vydáno:	Wiley 2023-01-01
Edice:	Clinical and Translational Science
On-line přístup:	https://doi.org/10.1111/cts.13423

Podobné jednotky

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
Autor: Maddalena Centanni, a další
Vydáno: (2020-03-01)

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
Autor: Eman I. K. Ibrahim, a další
Vydáno: (2023-09-01)

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Autor: Sarah Waliany, MD, MS, a další
Vydáno: (2019-09-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
Autor: Maria Dimou, a další
Vydáno: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
Autor: Elisabetta Abruzzese, a další
Vydáno: (2014-04-01)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
Autor: Nick Verougstraete, a další
Vydáno: (2022-03-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
Autor: Evan Pisick, a další
Vydáno: (2004-01-01)

Inhibition of c-Kit by tyrosine kinase inhibitors
Autor: Allison Galanis, a další
Vydáno: (2015-03-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
Autor: G. V. Lukina, a další
Vydáno: (2015-12-01)

Tyrosine Kinase Inhibitors Target B Lymphocytes
Autor: Nikki Lyn Esnardo Upfold, a další
Vydáno: (2023-02-01)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
Autor: Michael Ashby, a další
Vydáno: (2020-11-01)

Second-generation inhibitors of Bruton tyrosine kinase
Autor: Jingjing Wu, a další
Vydáno: (2016-09-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
Autor: Hor-Yue Tan, a další
Vydáno: (2018-02-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Autor: Lihua Huang, a další
Vydáno: (2015-09-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
Autor: Yi-fan Chen, a další
Vydáno: (2011-12-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
Autor: John J. Ryan, MD
Vydáno: (2016-12-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Autor: Yu Yao, a další
Vydáno: (2023-01-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
Autor: Ainun Nizar Masbuchin, a další
Vydáno: (2022-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
Autor: Xu H, a další
Vydáno: (2019-07-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Autor: Huang JT, a další
Vydáno: (2022-11-01)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
Autor: Zahra Moradpour, a další
Vydáno: (2019-01-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
Autor: Yifan Zhang, a další
Vydáno: (2024-06-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
Autor: Jiangnan Liu, a další
Vydáno: (2024-03-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Autor: Obada Ababneh, a další
Vydáno: (2022-05-01)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
Autor: Ahmad Assi, a další
Vydáno: (2023-12-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
Autor: Tasia Amelia, a další
Vydáno: (2022-01-01)

Flavonoids as receptor tyrosine kinase inhibitors in lung cancer
Autor: Sareshma Sudhesh Dev, a další
Vydáno: (2023-11-01)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
Autor: Chi-Hao Hu, a další
Vydáno: (2023-07-01)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
Autor: Ashraf El-Dabh, a další
Vydáno: (2019-07-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Autor: Qinlian Jiao, a další
Vydáno: (2018-02-01)

Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis
Autor: Diogo Alpuim Costa, a další
Vydáno: (2018-05-01)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
Autor: Vineet Agrawal, a další
Vydáno: (2015-02-01)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
Autor: Toshio Fujino, MD, a další
Vydáno: (2021-03-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Autor: D. Samuel Metibemu, a další
Vydáno: (2019-12-01)

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
Autor: Eliska Ruzickova, a další
Vydáno: (2019-10-01)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
Autor: Sachin Gupta, a další
Vydáno: (2008-10-01)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Autor: Domenico Ribatti
Vydáno: (2010-04-01)

A Review on Newer Tyrosine Kinase Inhibitors and their Uses
Autor: NITHU M KUMAR, a další
Vydáno: (2018-08-01)

Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors
Autor: Jianbing QIAO, a další
Vydáno: (2011-10-01)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
Autor: C. I. Edvard Smith, a další
Vydáno: (2021-11-01)